Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00027846 · OUTCOME

Event-free Survival (EFS)

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma · Source last updated 2019-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Probability of EFS at 5 years
Interval / dispersion
95% Confidence Interval
Time frame
At 5 years since the time of radiation therapy.

What was measured

EFS between centrally reviewed differentiated ependymoma and anaplastic ependymoma for the patients who had sub-total resection initially. The event-free survival (EFS) defined as the date of disease progression, disease relapse, occurrence of a second neoplasm, or death from any cause, measured from the start date of radiation therapy. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability.

Analysis population: Of 64 eligible patients who had initial subtotal resection, 5 patients were off-therapy prior to radiation therapy, and 4 patients had a disease progression prior to radiation therapy. There were 55 eligible patients included in the analysis. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability.

Groups in this outcome

Differentiated Ependymoma

Differentiated ependymoma:tumor pathology by central review.

Anaplastic Ependymoma

Anaplastic ependymoma:tumor pathology by central review.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Differentiated Ependymoma41
Anaplastic Ependymoma14

Reported measurements

Source class 1
Values in Probability of EFS at 5 years · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Differentiated Ependymoma0.424Not reported0.270.58Not reported
Anaplastic Ependymoma0.298Not reported0.050.54Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.27
        upper Limit
        0.58
        value
        0.424
      2. group Id
        OG001
        lower Limit
        0.05
        upper Limit
        0.54
        value
        0.298
denoms
  1. counts
    1. group Id
      OG000
      value
      41
    2. group Id
      OG001
      value
      14
    units
    Participants
description
EFS between centrally reviewed differentiated ependymoma and anaplastic ependymoma for the patients who had sub-total resection initially. The event-free survival (EFS) defined as the date of disease progression, disease relapse, occurrence of a second neoplasm, or death from any cause, measured from the start date of radiation therapy. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability.
dispersion Type
95% Confidence Interval
groups
  1. description
    Differentiated ependymoma:tumor pathology by central review.
    id
    OG000
    title
    Differentiated Ependymoma
  2. description
    Anaplastic ependymoma:tumor pathology by central review.
    id
    OG001
    title
    Anaplastic Ependymoma
param Type
NUMBER
population Description
Of 64 eligible patients who had initial subtotal resection, 5 patients were off-therapy prior to radiation therapy, and 4 patients had a disease progression prior to radiation therapy. There were 55 eligible patients included in the analysis. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability.
reporting Status
POSTED
time Frame
At 5 years since the time of radiation therapy.
title
Event-free Survival (EFS)
type
SECONDARY
unit Of Measure
Probability of EFS at 5 years

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice